{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:44:13Z","timestamp":1790484253847,"version":"4.1.0"},"reference-count":39,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CHU Angers, France"},{"name":"Nationwide Inserm"},{"name":"Inserm-Plan Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Radioiodine-refractory thyroid cancers have poor outcomes and limited therapeutic options (tyrosine kinase inhibitors) due to transient efficacy and toxicity of treatments. Therefore, combinatorial treatments with new therapeutic approaches are needed. Many studies link G protein\u2013coupled receptors (GPCRs) to cancer cell biology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To perform a specific atlas of GPCR expression in progressive and refractory thyroid cancer to identify potential targets among GPCRs aiming at drug repositioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed samples from tumor and normal thyroid tissues from 17 patients with refractory thyroid cancer (12 papillary thyroid cancers [PTCs] and 5 follicular thyroid cancers [FTCs]). We assessed GPCR mRNA expression using NanoString technology with a custom panel of 371 GPCRs. The data were compared with public repositories and pharmacological databases to identify eligible drugs. The analysis of prognostic value of genes was also performed with TCGA datasets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With our transcriptomic analysis, 4 receptors were found to be downregulated in FTC (VIPR1, ADGRL2\/LPHN2, ADGRA3, and ADGRV1). In PTC, 24 receptors were deregulated, 7 of which were also identified by bioinformatics analyses of publicly available datasets on primary thyroid cancers (VIPR1, ADORA1, GPRC5B, P2RY8, GABBR2, CYSLTR2, and LPAR5). Among all the differentially expressed genes, 22 GPCRs are the target of approved drugs and some GPCRs are also associated with prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>For the first time, we performed GPCR mRNA expression profiling in progressive and refractory thyroid cancers. These findings provide an opportunity to identify potential therapeutic targets for drug repositioning and precision medicine in radioiodine-refractory thyroid cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgab343","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:35:11Z","timestamp":1621269311000},"page":"2221-2232","source":"Crossref","is-referenced-by-count":11,"title":["G Protein\u2013coupled Receptors in Radioiodine-refractory Thyroid Cancer in the Era of Precision Medicine"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-8190","authenticated-orcid":false,"given":"Valentine","family":"Suteau","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019Endocrinologie-diab\u00e9tologie nutrition, CHU Angers, Angers, France"},{"name":"Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Seegers","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de l\u2019Ouest, Service de Biom\u00e9trie, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Munier","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Endocrinologie-diab\u00e9tologie nutrition, CHU Angers, Angers, France"},{"name":"Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France"},{"name":"Centre de r\u00e9f\u00e9rence des maladies rares de la Thyro\u00efde et des R\u00e9cepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rym","family":"Ben Boubaker","sequence":"additional","affiliation":[{"name":"Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Reyes","sequence":"additional","affiliation":[{"name":"Institut Curie, Plateforme G\u00e9nomique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gentien","sequence":"additional","affiliation":[{"name":"Institut Curie, Plateforme G\u00e9nomique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9line","family":"Wery","sequence":"additional","affiliation":[{"name":"Faculty of Health, University of Angers (CHU Angers), SFR ICAT, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Crou\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie Cellulaire et Tissulaire, CHU Angers, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Illouz","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Endocrinologie-diab\u00e9tologie nutrition, CHU Angers, Angers, France"},{"name":"Centre de r\u00e9f\u00e9rence des maladies rares de la Thyro\u00efde et des R\u00e9cepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France"},{"name":"Centre de comp\u00e9tence TUTHYREF, TUTHYREF Network, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hamy","sequence":"additional","affiliation":[{"name":"Service de chirurgie visc\u00e9rale, CHU d\u2019Angers, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Rodien","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Endocrinologie-diab\u00e9tologie nutrition, CHU Angers, Angers, France"},{"name":"Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France"},{"name":"Centre de r\u00e9f\u00e9rence des maladies rares de la Thyro\u00efde et des R\u00e9cepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France"},{"name":"Centre de comp\u00e9tence TUTHYREF, TUTHYREF Network, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Briet","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Endocrinologie-diab\u00e9tologie nutrition, CHU Angers, Angers, France"},{"name":"Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France"},{"name":"Centre de r\u00e9f\u00e9rence des maladies rares de la Thyro\u00efde et des R\u00e9cepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France"},{"name":"Centre de comp\u00e9tence TUTHYREF, TUTHYREF Network, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"issue":"8","key":"2021122204424771000_CIT0001","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"9940","key":"2021122204424771000_CIT0002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet."},{"issue":"7","key":"2021122204424771000_CIT0003","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus Placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2021122204424771000_CIT0004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol Pharmacol."},{"issue":"2","key":"2021122204424771000_CIT0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"2021122204424771000_CIT0006","first-page":"jbc.REV119.005601","article-title":"Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy","author":"Wu","year":"2019","journal-title":"J Biol Chem."},{"issue":"11","key":"2021122204424771000_CIT0007","doi-asserted-by":"crossref","first-page":"e3000434","DOI":"10.1371\/journal.pbio.3000434","article-title":"GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors","volume":"17","author":"Sriram","year":"2019","journal-title":"PLoS Biol."},{"issue":"9","key":"2021122204424771000_CIT0008","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40265-017-0738-9","article-title":"Pharmacotherapeutic targeting of G protein-coupled receptors in oncology: examples of approved therapies and emerging concepts","volume":"77","author":"Lappano","year":"2017","journal-title":"Drugs."},{"issue":"9","key":"2021122204424771000_CIT0009","first-page":"1798","article-title":"CD97: a dedifferentiation marker in human thyroid carcinomas","volume":"57","author":"Aust","year":"1997","journal-title":"Cancer Res."},{"issue":"2","key":"2021122204424771000_CIT0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/biom3020303","article-title":"Sphingosine 1-phosphate and cancer: lessons from thyroid cancer cells","volume":"3","author":"T\u00f6rnquist","year":"2013","journal-title":"Biomolecules."},{"issue":"6","key":"2021122204424771000_CIT0011","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1530\/ERC-17-0010","article-title":"Targeting the TSH receptor in thyroid cancer","volume":"24","author":"Rowe","year":"2017","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"2021122204424771000_CIT0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid."},{"issue":"5","key":"2021122204424771000_CIT0013","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2021122204424771000_CIT0014","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid."},{"issue":"1","key":"2021122204424771000_CIT0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000510174","article-title":"Digital multiplexed gene expression analysis of mRNA and miRNA from routinely processed and stained cytological smears: a proof-of-principle study","volume":"65","author":"Gentien","year":"2021","journal-title":"Acta Cytol."},{"key":"2021122204424771000_CIT0016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbt.2017.01.001","article-title":"Denaturing fixatives are compatible with the NanoString nCounter\u00ae platform and the Prosigna\u00ae assay","volume":"36","author":"Rouzier","year":"2017","journal-title":"New Biotechnol."},{"key":"2021122204424771000_CIT0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49247-1","article-title":"Validation of reference genes for normalization of relative qRT-PCR studies in papillary thyroid carcinoma","volume":"9","author":"Razavi","year":"2019","journal-title":"Sci Rep."},{"key":"2021122204424771000_CIT0018","volume-title":"Data from: G protein\u2013coupled receptors in progressive and radioiodine-refractory thyroid cancer in the era of precision medicine","author":"Suteau","year":"2021"},{"key":"2021122204424771000_CIT0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.mce.2018.09.005","article-title":"mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases","volume":"479","author":"Condello","year":"2019","journal-title":"Mol Cell Endocrinol."},{"issue":"7","key":"2021122204424771000_CIT0020","doi-asserted-by":"crossref","first-page":"research0034.1","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol."},{"issue":"52","key":"2021122204424771000_CIT0021","doi-asserted-by":"crossref","first-page":"19075","DOI":"10.1073\/pnas.0509603102","article-title":"The role of microRNA genes in papillary thyroid carcinoma","volume":"102","author":"He","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"2021122204424771000_CIT0022","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2015.05.046","article-title":"Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma","volume":"569","author":"Lan","year":"2015","journal-title":"Gene."},{"issue":"8","key":"2021122204424771000_CIT0023","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1073\/pnas.0610733104","article-title":"Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion","volume":"104","author":"Vasko","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"issue":"10","key":"2021122204424771000_CIT0024","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2014.665","article-title":"Revisiting the transcriptional analysis of primary tumours and associated nodal metastases with enhanced biological and statistical controls: application to thyroid cancer","volume":"112","author":"Tarabichi","year":"2015","journal-title":"Br J Cancer."},{"key":"2021122204424771000_CIT0025","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-017-0346-2","article-title":"Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas","volume":"9","author":"Beltrami","year":"2017","journal-title":"Clin Epigenetics."},{"issue":"7","key":"2021122204424771000_CIT0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000129","article-title":"A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers","volume":"4","author":"Yu","year":"2008","journal-title":"PLoS Genet."},{"key":"2021122204424771000_CIT0027","article-title":"Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets","volume":"8","author":"Nagy","year":"2018","journal-title":"Sci Rep."},{"issue":"9","key":"2021122204424771000_CIT0028","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090454","article-title":"Systematic meta-analysis identifies co-expressed kinases and GPCRs in ovarian cancer tissues revealing a potential for targeted kinase inhibitor delivery","volume":"11","author":"Albrecht","year":"2019","journal-title":"Pharmaceutics."},{"issue":"6","key":"2021122204424771000_CIT0029","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tips.2019.04.001","article-title":"GPCRomics: an approach to discover GPCR drug targets","volume":"40","author":"Insel","year":"2019","journal-title":"Trends Pharmacol Sci."},{"key":"2021122204424771000_CIT0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2020.10.004","article-title":"NanoString in the screening of genetic abnormalities associated with thyroid cancer","author":"Macerola","year":"2020","journal-title":"Semin Cancer Biol."},{"key":"2021122204424771000_CIT0031","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.2000.tb06947.x","article-title":"VPAC1 receptors and lung cancer","volume":"921","author":"Moody","year":"2000","journal-title":"Ann NY Acad Sci."},{"key":"2021122204424771000_CIT0032","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4674","article-title":"Bioinformatic analysis and identification of potential prognostic microRNAs and mRNAs in thyroid cancer","volume":"6","author":"Tang","year":"2018","journal-title":"Peer J."},{"key":"2021122204424771000_CIT0033","first-page":"e919820-1","article-title":"Lysophosphatidic acid receptor 5 (LPAR5) plays a significance role in papillary thyroid cancer via phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin (mTOR) pathway","volume":"26","author":"Wu","year":"2020","journal-title":"Med Sci Monit."},{"issue":"3","key":"2021122204424771000_CIT0034","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1677\/ERC-06-0048","article-title":"A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping","volume":"14","author":"Fujarewicz","year":"2007","journal-title":"Endocr Relat Cancer."},{"key":"2021122204424771000_CIT0035","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.28932","article-title":"Identification of key genes and pathways of thyroid cancer by integrated bioinformatics analysis","author":"Liu","year":"2019","journal-title":"J Cell Physiol."},{"issue":"1","key":"2021122204424771000_CIT0036","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1073\/pnas.1817325115","article-title":"Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis","volume":"116","author":"Duah","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"2021122204424771000_CIT0037","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/10428190701225882","article-title":"Transforming activity of purinergic receptor P2Y, G protein coupled, 8 revealed by retroviral expression screening","volume":"48","author":"Fujiwara","year":"2007","journal-title":"Leuk Lymphoma."},{"issue":"13","key":"2021122204424771000_CIT0038","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1158\/0008-5472.CAN-07-0883","article-title":"Combined targeting of endothelin a receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity","volume":"67","author":"Rosan\u00f2","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"2021122204424771000_CIT0039","first-page":"2295","article-title":"Integrated bioinformatics analysis of the association between apolipoprotein E expression and patient prognosis in papillary thyroid carcinoma","volume":"19","author":"Jiang","year":"2020","journal-title":"Oncol Lett."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab343\/38488686\/dgab343.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2221\/41847310\/dgab343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2221\/41847310\/dgab343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T23:46:45Z","timestamp":1640130405000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/8\/2221\/6277036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,5,17]]},"published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab343","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,5,17]]}}}